Announcements Trials
Browse Landscape

Phase

Phase 3 3

Status

Completed 5Terminated 4Active not recruiting 3Unknown 1

Sponsor Class

INDUSTRY 3

Study Type

Interventional 3

Sponsor

Cancer Type

Other hematologic neoplasm 3Lymphoid 3

Conditions

Lymphoma, Large B-Cell, Diffuse 32Lymphoma, Follicular 25Lymphoma, Mantle-Cell 23Lymphoma 22Leukemia, Lymphocytic, Chronic, B-Cell 22Lymphoma, Non-Hodgkin 21Lymphoma, B-Cell 16Lymphoma, B-Cell, Marginal Zone 13Neoplasms 8Recurrence 7Waldenstrom Macroglobulinemia 6Precursor Cell Lymphoblastic Leukemia-Lymphoma 5Leukemia 5Burkitt Lymphoma 5Neoplasm, Residual 3Lymphoproliferative Disorders 3Leukemia, Hairy Cell 3Hematologic Diseases 3Myelodysplastic Syndromes 2Lymphoma, AIDS-Related 2Leukemia, Myeloid, Acute 2Leukemia, Myeloid, Accelerated Phase 2Leukemia, Biphenotypic, Acute 2Blast Crisis 2Sarcoma, Myeloid 1Precursor B-Cell Lymphoblastic Leukemia-Lymphoma 1Neuritis 1Neoplasms, Plasma Cell 1Myeloproliferative Disorders 1Myeloid Diseases 1

Interventions

pirtobrutinib 5Tacrolimus 3Rituximab 3Mycophenolic Acid 3Cyclophosphamide 3venetoclax 2fludarabine phosphate 2fludarabine 2Whole-Body Irradiation 2Peripheral Blood Stem Cell Transplantation 2Patient Reported Outcome Measures 2Mesna 2Melphalan 2Busulfan 2Bendamustine Hydrochloride 2zanubrutinib 1isatuximab 1idelalisib 1ibrutinib 1acalabrutinib 1Vorinostat 1Ustekinumab 1Transplantation Conditioning 1Methotrexate 1Lenalidomide 1Interleukin-12 Subunit p40 1Immunoglobulin G 1Geriatric Assessment 1Disulfides 1Cyclosporine 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Active not recruiting × Hematologic Diseases × Rituximab × Clear all
NCT04666038 2026-04-24

BRUIN CLL-321

Eli Lilly and Company

Phase 3 Active not recruiting
238 enrolled 17 charts 1 FDA
LymphoidOther hematologic neoplasm

Hematologic Diseases, Lymphoma, Lymphoma, Non-Hodgkin, Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, B-Cell

NCT04965493 2026-01-29

BRUIN CLL-322

Eli Lilly and Company

Phase 3 Active not recruiting
600 enrolled
LymphoidOther hematologic neoplasm

Hematologic Diseases, Lymphoma, Non-Hodgkin, Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, B-Cell

NCT05023980 2026-01-22

BRUIN CLL-313

Eli Lilly and Company

Phase 3 Active not recruiting
309 enrolled
LymphoidOther hematologic neoplasm

Hematologic Diseases, Lymphoma, Non-Hodgkin, Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, B-Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡